General Information |
| Summary |
Since damaged articular cartilage does not regenerate spontaneously, current treatments rely on passive methods that focus on removing aggravating factors. The progressive degeneration and loss of articular cartilage are characteristic features of osteoarthritis. Even when surgically treating cartilage defects, regeneration often results in fibrocartilage rather than hyaline cartilage, which has the properties of healthy cartilage, making complete regeneration challenging.
Patients with osteoarthritis who experience persistent cartilage damage along with severe pain and loss of joint function often consider surgical treatment. In particular, for knee osteoarthritis, total knee arthroplasty (TKA) is commonly performed. However, due to the limited lifespan of artificial joints, TKA is not actively recommended for younger osteoarthritis patients.
Unlike existing transplantation-based treatments, MIUChon can be administered intra-articularly using a syringe in a clinical setting, reducing the surgical burden on patients and offering advantages as a non-surgical therapeutic option.
This research team aims to conduct a clinical study to evaluate the safety and exploratory efficacy of MIUChon, an induced pluripotent stem cell (iPSC)-derived chondrocyte aggregate, when administered to patients with osteoarthritis. |
| Clinical trials phase |
Not applicable |
| Start date (estimated) |
2025-04-17 |
| Clinical feature |
| Label |
Knee Osteoarthritis |
| Link |
http://purl.obolibrary.org/obo/NCIT_C215374 |
| Description |
Inflammation of the knee due to degeneration of the articular cartilage. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0010313 |
| Other study identifiers |
| Name |
KCT0010313 |
| Description |
Clinical Research Information Service (CRiS), Republic of Korea |
|
| Source weblink |
https://cris.nih.go.kr/cris/search/detailSearchEn.do?seq=29067 |
| Regulatory body approval |
| Name |
Korean Ministry of Food and Drug Safety (MFDS) |
| Country |
|
|
| Study sites |
|
| Sponsors |
The Catholic University of Korea, Seoul St. Mary's Hospital
|
Cells |
| Which differentiated cell type is used |
| Label |
chondrocyte |
| Link |
http://purl.obolibrary.org/obo/CL_0000138 |
| Description |
A skeletogenic cell that secretes a specialized, avascular, GAG-rich matrix, is embedded in cartilage tissue matrix, retains the ability to divide, and develops from a chondroblast cell.; Chondrocytes are specialized cells derived from the mesenchyme. They are the only cells found in healthy cartilage, and their primary function is the synthesis and maintenance of the extracellular matrix of cartilaginous tissues. They synthesize various molecules essential for biomechanical function, including collagen types II, IX, and XI, link proteins, and proteoglycans like aggrecan and decorin. Beyond structural integrity, chondrocytes also contribute significantly to the homeostasis of articular cartilage in joints.
The chondrocyte lifecycle involves proliferation, maturation, and hypertrophy, catering to growing, mature, and aging cartilage. Despite their typically low metabolic activity, conditions like osteoarthritis and rheumatoid arthritis can induce chondrocyte proliferation, leading to increased matrix production and the development of musculoskeletal issues. The unique extracellular matrix, rich in aggrecan, provides compression resistance, crucial for cartilage function in the musculoskeletal system.
(This extended description was generated by ChatGPT and reviewed by the CellGuide team, who added references, and by the CL editors, who approved it for inclusion in CL. It may contain information that applies only to some subtypes and species, and so should not be considered definitional.) |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
3 |
| Contact institutions/departments |
|
